Biocompatible materials for continuous glucose monitoring devices.
Biocompatible materials for continuous glucose monitoring devices.
复制标题
DOI：
10.1021/cr300387j
复制
发表时间：
2013-04-10
期刊：
影响因子：
62.1
通讯作者：
Schoenfisch, Mark H.
中科院分区：
文献类型：
--
作者：
Nichols, Scott P.;Koh, Ahyeon;Storm, Wesley L.;Shin, Jae Ho;Schoenfisch, Mark H.
糖尿病是一种世界性流行病，其特征是由于胰岛素缺乏或耐受而导致的慢性高血糖。1在美国，8.3%的人口目前患有糖尿病，如果目前的趋势继续下去，预计到2050年，这一数字将增加到三分之一的成年人。2因此，糖尿病是美国的第七大死因，每年的费用负担为1,740亿美元，其中包括1,160亿美元的直接医疗费用。2糖尿病患者的血糖水平全天波动显著，导致心脏病发作、中风、高血压、肾功能衰竭、失明和截肢等严重并发症。1、2便携式葡萄糖传感器使患者能够监测血糖水平、管理胰岛素水平，并降低糖尿病的发病率和死亡率。传统的血糖监测技术主要是基于电化学电流型葡萄糖传感器的使用。1987年，MediSense Inc.推出了第一款个人血糖检测设备，由试纸和读取器组成。自那时以来，已经推出了40多种不同的商业袖珍显示器。到目前为止，美国食品和药物管理局(FDA)已经批准了25台血糖监测仪，其中大多数使用了由固定在丝网印刷电极上的葡萄糖脱氢酶(GDH)或葡萄糖氧化酶(GOX)组成的试纸。4分析的基础是通过手指刺穿获取少量血液样本(<；1μL)，然后通过毛细作用将其引入试纸。3、4虽然这些监测仪通过改善血糖管理增加了糖尿病患者的健康结果，但这种监测只能提供无法预先警告高血糖或低血糖事件的瞬时血糖浓度。此外，样本采集方法(即手指刺法)不方便，导致患者依从性差。因此，人们一直在寻找能够持续监测血糖的分析方法。5连续血糖监测(CGM)提供关于一天中血糖波动的趋势(即血糖水平是上升还是下降)、幅度、持续时间和频率的实时信息。5、6理想情况下，具有分析功能的连续血糖监测设备可以连接到胰岛素输送泵上，创造出一个人造胰腺。5、6在本综述中，我们描述了
Diabetes mellitus is a worldwide epidemic characterized by chronic hyperglycemia that results from either a deficiency or tolerance in insulin. 1 In the United States, 8.3% of the population currently has diabetes and that number is projected to increase to 1 in 3 adults by 2050 if current trends continue. 2 As a consequence, diabetes is the seventh leading cause of death with an annual cost burden of $174 billion in the United States, including $116 billion in direct medical expenses. 2 Blood glucose levels in diabetics fluctuate significantly throughout the day, resulting in serious complications including heart attacks, strokes, high blood pressure, kidney failure, blindness and limb amputation. 1, 2 Portable glucose sensors give patients the ability to monitor blood glucose levels, manage insulin levels, and reduce the morbidity and mortality of diabetes mellitus. Traditional glucose monitoring techniques are primarily based on the use of electrochemical amperometric glucose sensors. In 1987, Medisense Inc. launched the first personal glucose testing device consisting of a test strip and reader. Over 40 different commercial pocket-sized monitors have been introduced since then. 3 To date, the US Food and Drug Administration (FDA) has approved> 25 glucose monitors with the majority employing test strips consisting of either glucose dehydrogenase (GDH) or glucose oxidase (GOx) immobilized on a screen-printed electrode. 4 The analysis is based on obtaining a small blood sample (< 1 μL) through a finger prick that is subsequently introduced into the test strip via capillary action. 3, 4 While these monitors have augmented the health outcomes for people with diabetes by improving blood glucose management, such monitoring only provides instantaneous blood glucose concentrations that are unable to warn of hyperglycemic or hypoglycemic events in advance. Additionally, the sample collection (ie, finger prick) method is inconvenient resulting in poor patient compliance. Analytical methods that enable continuous monitoring of blood glucose have thus been sought. 5 Continuous glucose monitoring (CGM) provides real-time information on trends (ie, whether the glucose levels are increasing or decreasing), magnitude, duration, and frequency of glucose fluctuations during the day. 5, 6 Ideally, analytically functional continuous glucose monitoring devices could be linked to an insulin delivery pump, creating an artificial pancreas. 5, 6 In this review, we describe progress in the
登录
查看更多内容
影响因子：
8.4
作者：
Cambiaso, A;Delfino, L;Vadgama, P
通讯作者：
Vadgama, P
影响因子：
5.4
作者：
Cameron, Brent D.;Anumula, Harini
通讯作者：
Anumula, Harini
影响因子：
7.4
作者：
Barman, Ishan;Kong, Chae-Ryon;Singh, Gajendra P.;Dasari, Ramachandra R.;Feld, Michael S.
通讯作者：
Feld, Michael S.
影响因子：
2.2
作者：
Amadeu, Thais P.;Seabra, Amedea. B.;Monte-Alto-Costa, Andrea
通讯作者：
Monte-Alto-Costa, Andrea
一氧化氮释放：第二部分。治疗应用。
影响因子：
46.2
作者：
Carpenter AW;Schoenfisch MH
通讯作者：
Schoenfisch MH